Hypogonadism Risk in Men Treated for Childhood Cancer.
(2009) In The Journal of clinical endocrinology and metabolism 94. p.4180-4186- Abstract
- Context: Pediatric cancer treatment may imply an increased risk of hypogonadism, leading to metabolic disorders and osteoporosis. Such complications are potentially preventable. Objective: The aim of this study was to assess diagnosis- and treatment-dependent risk of hypogonadism in male childhood cancer survivors (CCS). Design: Male CCS who were treated during the period 1970-2002 and who in 2004 were 18-45 yr of age were eligible. Setting: The study was conducted in a university hospital clinic. Patients: A consecutive group of CCS treated at Lund University Hospital was selected for the study, of whom 151 (38%) agreed to participate. Furthermore, 141 healthy fertile men served as controls. Interventions: We measured serum levels of free... (More)
- Context: Pediatric cancer treatment may imply an increased risk of hypogonadism, leading to metabolic disorders and osteoporosis. Such complications are potentially preventable. Objective: The aim of this study was to assess diagnosis- and treatment-dependent risk of hypogonadism in male childhood cancer survivors (CCS). Design: Male CCS who were treated during the period 1970-2002 and who in 2004 were 18-45 yr of age were eligible. Setting: The study was conducted in a university hospital clinic. Patients: A consecutive group of CCS treated at Lund University Hospital was selected for the study, of whom 151 (38%) agreed to participate. Furthermore, 141 healthy fertile men served as controls. Interventions: We measured serum levels of free and total testosterone, SHBG, and LH. Main Outcome Measures: Odds ratios (OR) for biochemical hypogonadism, defined as total testosterone less than 10 nmol/liter and/or LH above 10 IU/liter, were calculated and related to type of cancer, treatment received, as well as testicular volume. Results: Hypogonadism was more commonly detected in CCS than in controls (OR, 6.7; 95% CI, 2.7, 17). The increased presence of hypogonadism was noted in the following treatment groups: brain surgery, chemotherapy (with and without radiotherapy), and testicular irradiation. Low total testicular volume (</=24 ml) was associated with a high risk of hypogonadism (OR, 31; 95% CI, 11, 92). Conclusion: Adult male survivors of childhood cancer are at risk of hypogonadism, which should be acknowledged in the long-term follow-up of these men. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1500898
- author
- Romerius, Patrik LU ; Ståhl, Olof LU ; Moëll, Christian LU ; Relander, Thomas LU ; Cavallin-Ståhl, Eva LU ; Wiebe, Thomas LU ; Giwercman, Yvonne LU and Giwercman, Aleksander LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- The Journal of clinical endocrinology and metabolism
- volume
- 94
- pages
- 4180 - 4186
- publisher
- Oxford University Press
- external identifiers
-
- wos:000271470800009
- pmid:19789207
- scopus:70449101092
- ISSN
- 1945-7197
- DOI
- 10.1210/jc.2009-0337
- language
- English
- LU publication?
- yes
- id
- 6ffaa23f-ffd5-4cc4-8a0a-5fc1278aa817 (old id 1500898)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19789207?dopt=Abstract
- date added to LUP
- 2016-04-04 09:11:45
- date last changed
- 2022-03-15 18:09:59
@article{6ffaa23f-ffd5-4cc4-8a0a-5fc1278aa817, abstract = {{Context: Pediatric cancer treatment may imply an increased risk of hypogonadism, leading to metabolic disorders and osteoporosis. Such complications are potentially preventable. Objective: The aim of this study was to assess diagnosis- and treatment-dependent risk of hypogonadism in male childhood cancer survivors (CCS). Design: Male CCS who were treated during the period 1970-2002 and who in 2004 were 18-45 yr of age were eligible. Setting: The study was conducted in a university hospital clinic. Patients: A consecutive group of CCS treated at Lund University Hospital was selected for the study, of whom 151 (38%) agreed to participate. Furthermore, 141 healthy fertile men served as controls. Interventions: We measured serum levels of free and total testosterone, SHBG, and LH. Main Outcome Measures: Odds ratios (OR) for biochemical hypogonadism, defined as total testosterone less than 10 nmol/liter and/or LH above 10 IU/liter, were calculated and related to type of cancer, treatment received, as well as testicular volume. Results: Hypogonadism was more commonly detected in CCS than in controls (OR, 6.7; 95% CI, 2.7, 17). The increased presence of hypogonadism was noted in the following treatment groups: brain surgery, chemotherapy (with and without radiotherapy), and testicular irradiation. Low total testicular volume (</=24 ml) was associated with a high risk of hypogonadism (OR, 31; 95% CI, 11, 92). Conclusion: Adult male survivors of childhood cancer are at risk of hypogonadism, which should be acknowledged in the long-term follow-up of these men.}}, author = {{Romerius, Patrik and Ståhl, Olof and Moëll, Christian and Relander, Thomas and Cavallin-Ståhl, Eva and Wiebe, Thomas and Giwercman, Yvonne and Giwercman, Aleksander}}, issn = {{1945-7197}}, language = {{eng}}, pages = {{4180--4186}}, publisher = {{Oxford University Press}}, series = {{The Journal of clinical endocrinology and metabolism}}, title = {{Hypogonadism Risk in Men Treated for Childhood Cancer.}}, url = {{http://dx.doi.org/10.1210/jc.2009-0337}}, doi = {{10.1210/jc.2009-0337}}, volume = {{94}}, year = {{2009}}, }